Persistent Launches AI Drug Discovery Solution with NVIDIA for Faster Research

Persistent Systems has partnered with NVIDIA to develop advanced AI solutions for the healthcare and life sciences sector. The collaboration focuses on improving drug discovery using generative AI and data-driven technologies.

What the Partnership Aims to Achieve

The main goal of this collaboration is to help healthcare and life sciences companies:

• Speed up drug discovery processes
• Improve research accuracy
• Move from testing AI ideas to real-world applications

This is important as traditional drug research is slow, expensive, and complex.

New AI Solution: GenMolVS

Persistent has developed a new solution called Generative Molecules and Virtual Screening (GenMolVS).

This solution:

• Uses AI to design and test molecules digitally
• Simulates chemical and biological behaviour
• Helps researchers identify promising drug candidates faster

It is powered by NVIDIA’s advanced platforms like:

• BioNeMo
• NeMo Agent Toolkit
• AI Enterprise infrastructure

How the Technology Works

The solution uses AI models and intelligent agents to:

• Perform virtual screening of molecules
• Prioritise the best drug candidates
• Support planning for lab experiments

This allows scientists to:

• Test ideas digitally before physical lab trials
• Reduce risks in early-stage drug development
• Shorten research timelines from months to days

Benefits for Healthcare and Pharma Companies

The collaboration offers several advantages:

• Faster drug discovery cycles
• Lower research costs
• Better decision-making using real-time AI insights
• Higher chances of success in clinical trials

It also enables companies to use AI in real-world production environments, not just experiments.

Read More: Adani Enterprises Rights Issue: Second Call Payment Deadline Falls Today.

Strengthening AI Capabilities

Persistent will further enhance its AI capabilities by:

• Using NVIDIA’s AI infrastructure and computing systems
• Leveraging open AI models like Nemotron
• Training teams through NVIDIA’s certification programs

This will help build more advanced AI-driven platforms for global clients.

About Persistent Systems

Persistent Systems is a global digital engineering company offering services like:

• Software development
• Data and analytics
• Cloud computing
• AI and automation

The company operates in multiple countries and is part of key indices like Nifty Midcap 50 and S&P BSE 100.

Persistent Systems Share Price Movement

Persistent Systems share price (NSE: PERSISTENT) was trading at ₹4,542.90 on March 17, 2026, around 1:44 PM, down 2.07% (₹95.90) for the day. The stock opened at ₹4,689.00, which was also its intraday high, and later slipped to a low of ₹4,496.30.

Conclusion

The partnership between Persistent and NVIDIA marks a significant step in transforming drug discovery through AI. By combining advanced technology with scientific research, the solution aims to make drug development faster, more efficient, and more reliable, ultimately benefiting patients and the healthcare industry.

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.